3 key vaccine production challenges drugmakers are facing

Pfizer and Moderna both recently said their COVID-19 vaccine candidates are 95 percent effective in preventing the disease. The news is encouraging, but the U.S. is still a long way from manufacturing enough doses to inoculate its residents on a mass scale.

Below are three main challenges drugmakers are experiencing in their efforts to ramp up COVID-19 vaccine production.